A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523711-11-00

Enrollment

Registered

2026-04-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score at Week 5

Detailed description

Change from baseline in Clinical Global Impression -Severity (CGI-S) score at Week 5

Interventions

DRUGKarXT

DRUGKarXT Matching Placebo

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score at Week 5	—

Secondary

Measure	Time frame
Change from baseline in Clinical Global Impression -Severity (CGI-S) score at Week 5	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 21, 2026